FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Ricerca/Paper
Torna alla Biblioteca di Ricerca
PubMedReview

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.

Tucker Thomas J, Embrey Mark W, Alleyne Candice, Amin Rupesh P, Bass Alan, Bhatt Bhavana, Bianchi Elisabetta, Branca Danila, Bueters Tjerk, Buist Nicole
Journal of medicinal chemistry2021DOI: 10.1021/acs.jmedchem.1c01599
PCSK9 inhibitorstricyclic peptidesoral bioavailability

Punteggio Qualità

6/10

Citazioni

0

Soggetti

Non-Umani

Analisi di Peptide Contacts

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of PCSK9 inhibitors, tricyclic peptides, oral bioavailability in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: A solid contribution to PCSK9 inhibitors, tricyclic peptides, oral bioavailability research. Worth reading alongside other studies on the same compounds for a balanced picture.

Risultati Principali

The paper reviews the development of novel, highly potent tricyclic peptide PCSK9 inhibitors that are orally bioavailable and discusses their potential as next-generation therapeutics for hypercholesterolemia and coronary artery disease.

Limitazioni

As a review article, it does not present new experimental data but rather synthesizes existing knowledge. The focus is on preclinical development stages, lacking clinical trial outcomes.

Come Interpretare questa Ricerca

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Analisi di Peptide Contacts

Highlighting the innovative approach and potential clinical impact of novel tricyclic peptide inhibitors targeting PCSK9 in treating hypercholesterolemia and coronary artery disease.

PCSK9 inhibitorstricyclic peptidesoral bioavailability

Novel Tricyclic Peptides: A New Chapter in PCSK9 Inhibition for Heart Health

Published: May 17, 2026 | Source: Journal of medicinal chemistry (2021) | Category: PCSK9 inhibitors, tricyclic peptides, oral bioavailability

Overview

Researchers have developed a series of novel tricyclic peptide inhibitors targeting PCSK9, which could offer significant advancements in the treatment of hypercholesterolemia and coronary artery disease. These new compounds are highly potent and can be taken orally, marking a promising step forward in peptide therapy.

Study Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that regulates cholesterol levels by controlling the number of LDL receptors on liver cells. High levels of PCSK9 reduce the body's ability to clear low-density lipoprotein (LDL), commonly known as "bad" cholesterol, leading to an increased risk of heart disease. Previous research has shown that inhibiting PCSK9 can lower LDL cholesterol and improve cardiovascular outcomes. However, existing inhibitors often require injection or have limited oral bioavailability.

What the Research Found

The study reviewed by Tucker et al. focuses on a series of novel tricyclic peptide inhibitors designed to target PCSK9 more effectively than previous generations of drugs. These new peptides are highly potent and demonstrate excellent oral bioavailability, which is crucial for patient compliance and ease of use. The research highlights the structural modifications made to enhance potency and stability in vivo.

What This Means for Peptide Users

The development of these novel tricyclic peptide inhibitors could lead to more effective treatments for hypercholesterolemia and coronary artery disease that are easier for patients to manage. Oral administration is a significant advantage over existing injectable therapies, potentially increasing patient adherence and improving long-term outcomes.

Limitations and Caveats

As this paper is a review rather than presenting new experimental data, the findings rely heavily on preclinical studies. The lack of clinical trial outcomes means that the true efficacy and safety profiles in human patients remain to be determined. Additionally, while promising, these peptides must undergo rigorous testing before they can be considered for widespread use.

How This Compares to Previous Research

Previous research has established PCSK9 inhibitors as a valuable therapeutic option but highlighted challenges such as limited oral bioavailability and the need for frequent injections. The novel tricyclic peptide inhibitors discussed in this review address these issues, offering a potential breakthrough that could significantly enhance patient care.

Our Analysis

PeptideVault views this study positively due to its innovative approach and promising findings regarding the development of next-generation PCSK9 inhibitors. However, it is crucial to acknowledge that further clinical validation is necessary before definitive conclusions can be drawn about their efficacy and safety in humans.

Key Takeaways

  • The novel tricyclic peptide inhibitors represent a significant advancement in PCSK9 inhibition with high potency and oral bioavailability.
  • These peptides could improve patient compliance by offering an alternative to injectable therapies for managing hypercholesterolemia and coronary artery disease.
  • Further clinical trials are needed to confirm the safety and efficacy of these new compounds.

Original Source

Citation: Tucker Thomas J, Embrey Mark W, Alleyne Candice et al. (2021). A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.. Journal of medicinal chemistry. DOI: 10.1021/acs.jmedchem.1c01599

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota dell'Editor

Questa analisi è stata scritta dal team di ricerca di Peptide Contacts per rendere comprensibili i risultati complessi alla comunità dei peptide. Invitiamo i lettori a verificare il paper di sorgente per la metodologia e i dati completi. Per ulteriori informazioni su PCSK9 inhibitors, esplora le nostre guida della ricerca.

Citazione

Tucker Thomas J, Embrey Mark W, Alleyne Candice et al.. (2021). A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.. Journal of medicinal chemistry. https://doi.org/10.1021/acs.jmedchem.1c01599

Visualizza il testo integrale su PubMed

Papers Correlati

Esplora ulteriormente

Questo contenuto è derivato da ricerche peer-reviewed per scopi educativi solo. Non costituisce consiglio medico. Consulta sempre un professionista sanitario qualificato prima di utilizzare qualsiasi terapia basata su peptide.